APA

Smit E. F., Wu Y., Gervais R., Zhou C., Felip E., Feng J., Guclu S. Z., Hoiczyk M., Dorokhova E., Freudensprung U., Grange S., Perez-Moreno P. D., Mitchell L. & Reck M. (20171207). A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). : Lung cancer (Amsterdam, Netherlands).

Chicago

Smit Egbert F, Wu Yi-Long, Gervais Radj, Zhou Caicun, Felip Enriqueta, Feng Jifeng, Guclu Salih Zeki, Hoiczyk Mathias, Dorokhova Elena, Freudensprung Ulrich, Grange Susan, Perez-Moreno Pablo Diego, Mitchell Lada and Reck Martin. 20171207. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). : Lung cancer (Amsterdam, Netherlands).

Harvard

Smit E. F., Wu Y., Gervais R., Zhou C., Felip E., Feng J., Guclu S. Z., Hoiczyk M., Dorokhova E., Freudensprung U., Grange S., Perez-Moreno P. D., Mitchell L. and Reck M. (20171207). A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). : Lung cancer (Amsterdam, Netherlands).

MLA

Smit Egbert F, Wu Yi-Long, Gervais Radj, Zhou Caicun, Felip Enriqueta, Feng Jifeng, Guclu Salih Zeki, Hoiczyk Mathias, Dorokhova Elena, Freudensprung Ulrich, Grange Susan, Perez-Moreno Pablo Diego, Mitchell Lada and Reck Martin. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). : Lung cancer (Amsterdam, Netherlands). 20171207.